A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease

Mike Taylor,1 George Ousler,2 Gail Torkildsen,3 Claire Walshe,1 Matthew C T Fyfe,1 Adele Rowley,1 Steve Webber,1 John D Sheppard,4 Ajay Duggal1 1TopiVert Pharma Limited, London, UK; 2Ora Inc., Andover, MA, USA; 3Andover Eye Associates, Andover, MA, USA; 4Virginia Eye Consultants, Norfolk, VA, USA...

Full description

Saved in:
Bibliographic Details
Main Authors: Taylor M, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, Webber S, Sheppard JD, Duggal A
Format: article
Language:EN
Published: Dove Medical Press 2019
Subjects:
Dry Eye
DED
TOP1630
Ocular Inflammation
Ophthalmology
RE1-994
Online Access:https://doaj.org/article/a6447234955b44e08b83b58e5c0fbf7c
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/a6447234955b44e08b83b58e5c0fbf7c

Similar Items